There is currently no standard treatment regimen for COPD; it is, therefore, vital to develop a therapeutic agent, and Slit2 shows potential as a treatment candidate based on its regenerative effects. The gene discussed is SLIT2; the disease is chronic obstructive pulmonary disease.